CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

CVS says the decision to cover Wegovy and exclude Zepbound is “forcing the drug manufacturers to compete with one another” and will encourage both Eli Lilly and Novo Nordisk to lower prices for ... a ...

Some common medications can lead to vitamin and mineral deficiencies. Learn which drugs can interact in this way.

How much can A1C drop in 3 months without medication? Your results can vary depending on your starting point and how many healthy changes you make, but it's possible to lower your A1C by up to 2.5 ...

Policymakers will need to address the true drivers of high drug prices here at home, while simultaneously pressing our allies to contribute more abroad, writes PhRMA’s Steve Ubl.

Tens of thousands of people suffer needless heart attacks and strokes every year because they aren't taking cholesterol-lowering drugs, a new study says.

The investigational compound SAP-001 had a sustained effect on serum urate levels vs placebo, but not on gout flares in a Phase 2b study.

The plan to lower drug prices by cracking down on pharmacy benefit managers arrived on Gov. JB Pritzker's desk Monday.

Tens of thousands of heart attacks and strokes could be avoided each year if cholesterol-lowering drugs were used according to guidelines New study details gaps between actual and recommended use ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing dementia.

Pitavastatin is a novel statin that induces plaque regression and is superior to simvastatin and to pravastatin in the elderly.